Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

Document › Details

Activiomics Ltd.. (11/22/12). "Press Release: Activiomics Signs Research Agreement with Kyowa Hakko Kirin as Part of Its Strategic Partnership with BioFocus".

	Organisation	Activiomics Ltd.
	Group	Retroscreen Virology (Group)
	Organisation 2	Kyowa Hakko Kirin Co., Ltd.
	Today	Kyowa Kirin Co., Ltd.
	Group	Kyowa Kirin (Group)
	Product	TIQUAS technology (Targeted In-depth Quantification of cell Signalling)
	Product 2	drug discovery services
	Index term	Kyowa Hakko Kirin–Activiomics: mass spectrometry services, 201211– supply research services using TIQUAS technology within BioFocus partnership
	Index term 2	Galapagos–Activiomics: proteomic services, 201207– collab strategic alliance providing services via BioFocus using TIQUAS mass spec technology
	Person	Ohshima, Etsuo (Kyowa Hakko Kirin 201211 Managing Officer + VP, Head Research Division)
	Person 2	Torbett, Neil (PhoreMost 201701– CBO Activiomics 201211 COO)

Activiomics today announces it has signed a research agreement with the Japanese pharmaceutical company Kyowa Hakko Kirin. Under the agreement, Activiomics will apply its novel TIQUAS phosphoproteomics platform to elucidate signalling mechanisms of lead compounds in relevant cell-based systems. This agreement was signed as part of Activiomics' recently announced strategic partnership with BioFocus.

Activiomics partners with Pharma and Biotech using its innovative mass spectrometry based methods to analyse and interpret cell signalling pathway activity, generating high value information for the pharmaceutical and biotechnology industry.

"We've engaged with Activiomics because we recognise that Activiomics' label free phosphoproteomics approach can provide unique insights into signalling pathway activity, information that can complement and extend our existing gene expression datasets. This technology will enable us to better understand cell signalling mechanisms of our lead compounds and could enable us to identify important biomarkers" said Etsuo Ohshima, Ph.D., managing officer and vice president, head, research division at Kyowa Hakko Kirin.

Dr Neil Torbett, COO of Activiomics, said: "We are delighted to have signed this agreement with Kyowa Hakko Kirin. This is a further endorsement of our technology platform and also represents Activiomics' first entry into the Japanese market. Activiomics has received invaluable support from BioFocus in establishing this collaboration, a clear demonstration of our strategic partnership in action".

Dr Chris Newton, Managing Director of BioFocus, commented "BioFocus is pleased to have participated in the signing of this deal, which we intend to be the first of many. Future deals will add together BioFocus' drug discovery capabilities and Activiomics' phosphoproteomics platform for the furtherance of our clients' projects".

For more information, please contact:

Activiomics Ltd. Mark Warne, CEO, Tel: +44 845 5195 091
BioFocus: Chris Newton, Managing Director, Tel: + 44 1799 533 500

Record changed: 2019-06-09